Evidence Level
PQQ (Pyrroloquinoline Quinone) is a compound that has gained attention for its potential benefits in mitochondrial function and cognitive health. Research by Chowanadisai et al. (2010) demonstrated that PQQ activates the transcriptional coactivator PGC-1α, which promotes mitochondrial biogenesis in cell models. This mechanism suggests that PQQ may enhance mitochondrial function and protection.
A pivotal human trial conducted by Itoh et al. (2016) investigated the cognitive effects of PQQ supplementation. In a randomized, placebo-controlled study involving 41 elderly subjects, daily administration of 20 mg BioPQQ™ for 12 weeks improved selective attention and visual-spatial cognitive function in participants with lower initial scores. These findings highlight PQQ's potential to support cognitive health in aging populations.
Additionally, Harris et al. (2013) explored the safety, bioavailability, and physiological effects of PQQ in humans. Their crossover study (n=10) revealed that PQQ supplementation decreased inflammation markers such as C-reactive protein (CRP) and interleukin-6 (IL-6), while also improving mitochondrial function. These results underscore PQQ's role in modulating inflammatory processes and enhancing metabolic health.
The synergy between PQQ and CoQ10 is notable, as PQQ facilitates mitochondrial biogenesis while CoQ10 optimizes mitochondrial energy production. Although the evidence base for PQQ remains emerging with relatively small human trials, its unique mechanism of action sets it apart from other longevity compounds.